Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
100.00%
Operating Margin
89.64%
Net Margin
126.47%
Efficiency Metrics
Revenue per Expense Ratio
9.65
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
0.00%
Income Tax Rate
0.00%
EPS
1.4200000000
Balance Sheet Analysis
Current Ratio
0.00
Cash Ratio
0.02
Working Capital
$-685.71M
Debt to Equity
0.55
Debt to Assets
33.46%
Equity Ratio
61.28%
Cash Flow Analysis
Operating Cash Flow Ratio
61.28%
Free Cash Flow Ratio
61.28%
CapEx to Revenue
0.00%
Dividends Paid
$94.13M
Stock Buybacks
$1.82M
Total Shareholder Returns
$95.95M
Cash Position Change
-97.70%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 0.18%
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
137.37%
Net Income
147.20%
EPS
147.49%
Operating Income
134.68%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
2,638.01%
Operating Cash Flow
-5.42%
Free Cash Flow
-5.42%
Balance Sheet Health
Assets
2.90%
Debt
0.27%
Book Value per Share
3.66%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
0.18%
Shares Outstanding
-0.20%
Long Term Trends
3Y Revenue/Share
-36.05%
5Y Revenue/Share
-45.15%
3Y Dividend/Share
-0.74%
5Y Dividend/Share
22.63%